Lovotibeglogene autotemcel
| Clinical data | |
|---|---|
| Trade names | Lyfgenia |
| Other names | bb1111, lovo-cel, LentiGlobin for sickle cell disease |
| AHFS/Drugs.com | Lyfgenia |
| License data | |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| DrugBank | |
| UNII | |
| KEGG | |
Lovotibeglogene autotemcel, sold under the brand name Lyfgenia, is a lentiviral gene therapy used for the treatment of sickle cell disease.
The most common side effects include stomatitis (mouth sores of the lips, mouth, and throat), low levels of platelets, white blood cells, and red blood cells, and febrile neutropenia (fever and low white blood cell count), consistent with chemotherapy and underlying disease.
The US Food and Drug Administration (FDA) approved lovotibeglogene autotemcel in December 2023.